Johannes Cornelis De Jong

Title: Johannes Cornelis De Jong: Innovator in Heterocyclic H3 Antagonists

Introduction

Johannes Cornelis De Jong is a notable inventor based in Groningen, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that interact with the histamine H3 receptor. His innovative work has led to the filing of a patent that showcases his expertise in medicinal chemistry.

Latest Patents

De Jong holds a patent for "Heterocyclic H3 antagonists," which describes a compound of formula (I) wherein W, X, Y, Z is —C(R)≡ or N. The patent details that R can be hydrogen or alkyl, V is N or C, and A is a bond or an alkylene linker with 1 to 3 carbon atoms. The compound has a binding affinity for the histamine H3 receptor, making it a valuable asset in pharmaceutical research. He has 1 patent to his name.

Career Highlights

Currently, De Jong is associated with High Point Pharmaceuticals, LLC, where he continues to advance his research in drug development. His work is characterized by a strong focus on creating effective therapeutic agents that can address various medical conditions.

Collaborations

Throughout his career, De Jong has collaborated with esteemed colleagues such as Rolf Hohlweg and Jane Marie Lundbeck. These partnerships have fostered a collaborative environment that enhances the innovation process in pharmaceutical research.

Conclusion

Johannes Cornelis De Jong is a prominent figure in the field of pharmaceutical innovation, with a focus on heterocyclic compounds. His contributions through patents and collaborations highlight his commitment to advancing medical science.